Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis.
Ann Oncol
; 33(3): 321-329, 2022 03.
Article
in En
| MEDLINE
| ID: mdl-34954044
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Brain Neoplasms
/
Breast Neoplasms
Type of study:
Clinical_trials
/
Guideline
Limits:
Female
/
Humans
Language:
En
Journal:
Ann Oncol
Journal subject:
NEOPLASIAS
Year:
2022
Document type:
Article
Country of publication: